# Emerging Therapies for COVID-19: the value of more clinical research compared to immediate implementation.
Stijntje W. Dijk[1], Eline Krijkamp[1], Natalia Kunst [2,3,4]
Cary P. Gross[4], John B. Wong[5], Myriam G.M. Hunink*[1,6]

1 Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
2 Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, USA
3 Department of Health Management and Health Economics, Institute of Health and Society, Faculty of Medicine, Oslo, Norway
4 Section of General Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
5 Division of Clinical Decision Making, Tufts Medical Center, Boston, USA
6 Center for Health Decision Science, Harvard University T.H. Chan School of Public Health, Boston, USA

*Corresponding author, m.hunink@erasmusmc.nl
